M
MicuRx Pharmaceuticals
MicuRx discovers and develops novel antibiotics to prevent and treat drug-resistant bacterial infections
About MicuRx Pharmaceuticals
Founded in 2007 and headquartered in Shanghai, with branches in California, Hong Kong, and Beijing, MicuRx is a biopharmaceutical company specializing in novel therapeutics for infectious diseases. The company focuses on addressing the growing issue of global antimicrobial resistance by developing innovative drugs for unmet medical needs. MicuRx operates in the biopharmaceutical market, serving patients who suffer from common and serious drug-resistant bacterial infections. The company's business model revolves around the discovery, development, and commercialization of these innovative drugs. Revenue is generated through the sale of these therapeutics, including products like the Contezolid tablet, which has been added to China's National Reimbursement Drug List (NRDL). MicuRx employs a China-US parallel development strategy and adheres to international standards, leveraging the expertise of an international core scientific and management team. The company aims to be a respected leader in the field of innovative medicines, providing superior and differentiated therapeutic products to patients.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2007
- Headquarters
- Foster City, United States
- Listing
- IPO 2022
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 31.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $138M | — | Haijing Pharmaceutical | ↗ |
| IPOOther financing | Aug 2022 | $0 | — | Undisclosed | — |
Growth signals
Latest recorded traffic for MicuRx Pharmaceuticals is 2.1K monthly website visits, up 40% over the last three months. MicuRx Pharmaceuticals's team declined 8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Morningside
BVCF- DBDevon Park BioVentures
Series B and later11 investors entered at this stage
- GCGP Healthcare Capital
Delian Capital
Huagai Capital
CICC
Hg Capital
Zero2IPO
Legend Capital
Founder Securities
Korea Investment Partners
Yingke Capital- HPHaijing Pharmaceutical
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MicuRx Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MicuRx Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.